Investing in its long-term pipeline, Genentech has signed three discovery deals with Skyhawk Therapeutics, Sosei Heptares and Convelo Therapeutics for a total potential deal value of US$3 B combined. The deals delve Genentech deeper into modalities in which it has prior experience through partnerships – RNA splicing, G protein-coupled receptor agonists and remyelination therapies.